Belatacept and Long-Term Outcomes in Kidney Transplantation

This randomised controlled trail compared kidney transplant recipients compared a more-intensive belatacept regimen, a less-intensive belatacept regimen, or a cyclosporine regimen over an 84 month period.  Seven years after transplantation, patient and graft survival and the mean estimated glomerular filtration rate (eGFR) were significantly higher for both belatacept regimes than for cyclosporine.

The article was published in the New England journal of medicine, vol. 374, no. 4, p. 333-343 (January 28, 2016).  The full text can be seen in the Healthcare Library on D Level of Rotherham Hospital or via this link.  Please note that most articles in the NEJM are not available freely full text hence the library has a subscription to the physical journal.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s